Syndax Pharmaceuticals Inc - Common Stock, par value $0.0001 per share (SNDX)

Historical Holders from Q1 2016 to Q3 2025

Symbol
SNDX on Nasdaq
Type / Class
Equity / Common Stock, par value $0.0001 per share
Shares outstanding
86.6M
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
101M
Holdings value
$1.56B
% of all portfolios
0.006%
Grand Portfolio weight change
+0%
Number of holders
223
Number of buys
120
Number of sells
-98
Average Value change %
0%
Average buys %
+0.002%
Average sells %
-0.002%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Syndax Pharmaceuticals Inc - Common Stock, par value $0.0001 per share (SNDX)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Kynam Capital Management, LP 9.98% $114M 8.52M Kynam Capital Management, LP 31 Dec 2024
BlackRock, Inc. 7.8% $89.9M 6.74M BlackRock, Inc. 31 Mar 2025
GOLDMAN SACHS GROUP INC 6.5% +26% $51.6M $9.9M 5.58M +23.7% THE GOLDMAN SACHS GROUP, INC. 30 Jun 2025
Point72 Asset Management, L.P. 5% +76.7% $44.6M $20.8M 4.33M +87.5% Point72 Asset Management, L.P. 15 Aug 2025
MORGAN STANLEY 2.4% -65% $27.2M -$44.3M 2.04M -62% Morgan Stanley 31 Mar 2025
WELLINGTON MANAGEMENT GROUP LLP 0% $476K 35.7K Wellington Management Group LLP 28 Feb 2025

Institutional Holders of Syndax Pharmaceuticals Inc - Common Stock, par value $0.0001 per share (SNDX)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 101M $1.56B +$19.1M $15.39 223
2025 Q2 102M $953M -$3.41M $9.37 214
2025 Q1 101M $1.24B +$32.3M $12.29 215
2024 Q4 98M $1.3B +$87.2M $13.22 214
2024 Q3 89M $1.71B +$23M $19.25 208
2024 Q2 87.4M $1.79B -$71.1M $20.53 195
2024 Q1 90.3M $2.15B +$46M $23.80 188
2023 Q4 88.7M $1.92B +$406M $21.61 176
2023 Q3 71M $1.03B -$1.24M $14.52 174
2023 Q2 70.7M $1.48B -$48.4M $20.93 165
2023 Q1 73M $1.54B +$23.7M $21.12 161
2022 Q4 71.5M $1.82B +$263M $25.45 159
2022 Q3 60M $1.44B +$97.8M $24.03 136
2022 Q2 55.2M $1.06B +$21.5M $19.24 116
2022 Q1 54.6M $948M -$36.4M $17.38 136
2021 Q4 52.4M $1.15B +$54.3M $21.89 129
2021 Q3 49.1M $938M -$20.7M $19.11 121
2021 Q2 50.2M $862M +$12.3M $17.17 113
2021 Q1 48.5M $1.08B +$46.5M $22.36 130
2020 Q4 46.5M $1.03B +$270M $22.24 140
2020 Q3 34.2M $505M +$23.5M $14.76 98
2020 Q2 32.6M $484M +$177M $14.82 96
2020 Q1 20.8M $228M +$45.4M $10.97 81
2019 Q4 16.7M $146M -$3.74M $8.78 71
2019 Q3 17.1M $128M -$812K $7.47 72
2019 Q2 17.2M $160M +$3.97M $9.31 71
2019 Q1 17M $89M +$8.09M $5.25 66
2018 Q4 15.5M $68.8M -$2.73M $4.45 73
2018 Q3 15.3M $124M +$3.41M $8.08 73
2018 Q2 15.1M $106M -$23.3M $7.02 83
2018 Q1 17.2M $244M +$5.18M $14.23 72
2017 Q4 17.2M $150M +$15.9M $8.76 77
2017 Q3 15M $176M -$8.29M $11.70 67
2017 Q2 15.7M $219M +$56.8M $13.97 63
2017 Q1 11.7M $160M +$30.2M $13.72 62
2016 Q4 11.1M $79.8M -$4.87M $7.17 55
2016 Q3 11.6M $176M +$19.9M $15.16 45
2016 Q2 10.3M $101M +$10.8M $9.85 46
2016 Q1 9.44M $126M +$126M $13.32 27